An Investigation of Delta-9-tetrahydrocannabinol (THC) and Cannabidiol (CBD) in Multiple Sclerosis Patients
Status:
Completed
Trial end date:
2002-07-01
Target enrollment:
Participant gender:
Summary
A study to compare the efficacy of GW-1000-02 [named Sativex® in Canada and also named
Sativex® Oromucosal Spray] with placebo in relieving five key symptoms of Multiple Sclerosis
after six weeks of therapy.